Rituximab therapy for refractory steroid-resistant nephrotic syndrome in children

Koichi Kamei(National Center For Child Health and Development), Kazumoto Iijima(Kobe Children's Hospital), Kandai Nozu(Kobe Children's Hospital), Shuichi Ito(Yokohama City University), Kenji Ishikura(Kitasato University), Mayumi Sako(National Center For Child Health and Development)

Pediatric Nephrology

December 18, 2018

10.1007/s00467-018-4166-1

Cited by 63

Related Papers

Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial

|The Lancet|2014|450

IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome

|Pediatric Nephrology|2022|278

Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease

|Clinical and Experimental Nephrology|2013|267

Epidemiology of pediatric chronic kidney disease/kidney failure: learning from registries and cohort studies

|Pediatric Nephrology|2021|149

A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment

|Kidney International|2014|135